| 贺楠楠.养血逐寒方治疗风湿寒性关节痛的临床研究[J].实用中西医结合临床,2023,23(7):10-13 |
| 养血逐寒方治疗风湿寒性关节痛的临床研究 |
| Clinical Study of Yangxuezhuhan Prescription in the Treatment of Wind-Dampness-Cold Arthralgia |
| |
| DOI： |
| 中文关键词: 风湿寒性关节痛 养血逐寒方 中医证候积分 血液流变学指标 |
| 英文关键词: Wind-dampness-cold arthralgia Yangxuezhuhan prescription TCM syndrome score Hemorheology index |
| 基金项目: |
|
| 摘要点击次数: 112 |
| 全文下载次数: 64 |
| 中文摘要: |
| 目的：观察养血逐寒方治疗风湿寒性关节痛的临床研究。方法：选取2019年5月至2021年11月收治的风湿寒性关节痛患者102例，按随机数字表法分为对照组与观察组，各51例。对照组口服塞来昔布治疗，观察组口服塞来昔布同时联合养血逐寒方治疗。对比两组临床疗效、治疗前后患者血液流变学指标（红细胞比容、红细胞刚性指数及全血低切还原黏度）、中医证候（关节疼痛及屈伸不利、肌肉酸麻疼痛或肿胀、口淡不欲饮等）积分、疼痛量表[视觉模拟评分法（VAS）]评分、膝关节功能（LKSS）评分、生活质量（GQOLI-74）评分及不良反应。结果：观察组治疗总有效率为96.08%（49/51），高于对照组的84.31%（43/51）（P＜0.05）；治疗前，两组中医证候积分、血液流变学指标、VAS评分、LKSS评分及GQOLI-74评分比较，差异无统计学意义（P＞0.05）；治疗后，两组中医证候积分、血液流变学指标、VAS评分、LKSS评分及GQOLI-74评分均优于治疗前，且观察组优于对照组（P＜0.05）；两组不良反应发生率对比，差异无统计学意义（P＞0.05）。结论：养血逐寒方可显著提升风湿寒性关节痛患者临床疗效，改善患者膝关节功能，提高生活质量，且未增加不良反应。 |
| 英文摘要: |
| Objective: To observe the clinical study of Yangxuezhuhan prescription on wind-dampness-cold arthralgia. Methods: A total of 102 patients with wind-dampness-cold arthralgia admitted from May 2019 to November 2021 were selected and divided into control group and observation group according to random number table method, with 51 cases in each group.The control group was treated with oral celecoxib, while the observation group was treated with oral celecoxib combined with Yangxuezhuhan prescription.The clinical efficacy, hemorheology index (erythrocyte volume, erythrocyte rigidity index and whole blood low cut reduction viscosity), TCM syndrome scores (joint pain and adverse flexion and extension, muscle pain or swelling, mouth weakness, etc.), pain scale [visual analog scale (VAS)] score, knee function (LKSS) score and quality of life of the two groups were compared before and after treatment Dose (GQOLI-74) score and adverse reactions. Results: The total effective rate was 96.08% (49/51) in the observation group and 84.31% (43/51) in the control group, which was higher in the observation group (P＜0.05). Before treatment, there was no significant difference in TCM syndrome score, hemorheology index, VAS score, LKSS score and GQOLI-74 score between the two groups (P＞0.05). After treatment, TCM syndrome score, hemorheology index, VAS score, LKSS score and GQOLI-74 score in both groups were better than before treatment, and the observation group was better than the control group (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion: Yangxuezhuhan prescription can significantly improve the clinical effect of wind-dampness-cold arthralgia patients, improve the knee function of patients, improve the quality of life, and do not increase adverse reactions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
